Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Dec 11, 2017 - Dr. Kenneth Hillan to become President, R&D - - Succession designed to lead Achaogen through next phase of growth as a commercial-stage company - - Transition effective January 1, 2018 - SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NE...
Nov 30, 2017 SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that management will be hosting investor meetings at the Guggenheim Securities ...
Nov 24, 2017 SOUTH SAN FRANCISCO, Calif., Nov. 24, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on November 20, 2017, the compensation committee of the Company's board of d...
Nov 8, 2017 -- Plazomicin New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTI) and bloodstream infections (BSI) -- -- C-Scape, an orally-administered antibacterial candidate, was awarded a BARDA contract ...
Nov 6, 2017 -- Company presentation scheduled for November 14, 2017 at 8:45 a.m. EST -- SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infecti...
Oct 30, 2017 SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its third quarter financial results on Wednes...
Oct 27, 2017 SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on October 21, 2017, the compensation committee of the Company's board of di...
Oct 26, 2017 -- Investigational drug has potential to treat certain MDR gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) -- SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antib...
Oct 5, 2017 -- Presentations emphasize potential role for plazomicin in treating bloodstream infections (BSI) due to carbapenem-resistant Enterobacteriaceae (CRE) as well as potential long-term clinical benefits for patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP) -- SOUTH SAN FRANCI...
Sep 28, 2017 Non-dilutive funding to support clinical development of antibacterial candidate for ESBL infections Company expects top-line Phase 1 results in 2017 and initiation of pivotal Phase 3 trial in 2018 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE...
Page:
1
... NextLast
= add release to Briefcase